TaeHong Park

Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer

CT-P16 (Vegzelma ® ) is a bevacizumab biosimilar approved for indications including non-squamous non-small cell lung cancer. We developed an integrated population pharmacokinetic model pooling data from two phase I studies in healthy subjects and one phase III study in patients w...